Table 4. Mean changes in peripheral CD19+ and CD20+ B lymphocyte following HLX01 and reference rituximab administration (phase 1b study).

Time point	Statistics	CD19+ B cell (count/µL)			CD20+ B cell (count/µL)
		HLX01 (N=43)	Reference rituximab (N=43)		HLX01 (N=43)	Reference rituximab (N=43)
Reference rituximab was sourced from China (MabThera®; rituximab-CN); 375 mg/m2 of HLX01 or reference rituximab was administered.
Baseline	n (miss)	43 (0)	42 (1)		43 (0)	42 (1)
	Mean	114.7	132.8		112.0	132.7
	Median	55.0	94.6		54.0	96.5
	Min, Max	0.1, 591.1	0.1, 632.7		0, 522.9	0, 629.1
5 min after infusion	n (miss)	43 (0)	42 (1)		43 (0)	42 (1)
	Mean	1.8	0.9		0.1	0.1
	Median	0.3	0.7		0.0	0.1
	Min, Max	0, 32.3	0, 4.1		0, 0.7	0, 0.6
24 h after infusion	n (miss)	43 (0)	42 (1)		43 (0)	42 (1)
	Mean	1.5	1.4		0.1	0.1
	Median	0.6	1.0		0.0	0.0
	Min, Max	0, 17.5	0, 6.4		0, 0.3	0, 0.7
14 d after infusion	n (miss)	42 (1)	42 (1)		42 (1)	42 (1)
	Mean	0.6	0.6		0.1	0.1
	Median	0.4	0.3		0.0	0.1
	Min, Max	0, 4.6	0, 5.5		0, 0.7	0, 0.8
56 d after infusion	n (miss)	42 (1)	42 (1)		42 (1)	42 (1)
	Mean	2.0	0.5		1.7	0.3
	Median	0.4	0.3		0.2	0.2
	Min, Max	0, 58.4	0, 2.9		0, 59.0	0, 1.1
91 d after infusion	n (miss)	42 (1)	42 (1)		42 (1)	42 (1)
	Mean	4.2	1.2		4.1	1.0
	Median	0.3	0.3		0.3	0.2
	Min, Max	0, 142.4	0, 34.1		0, 142.4	0, 34.1